At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DRTS Alpha Tau Medical
Market Closed 04-04 16:00:00 EDT
2.52
+0.04
+1.61%
盘后2.52
+0.000.00%
16:00 EDT
| High2.53 | Low2.30 | Vol96.52K |
| Open2.43 | D1 Closing2.48 | Amplitude9.07% |
| Mkt Cap177.36M | Tradable Cap131.48M | Total Shares70.38M |
| T/O230.14K | T/O Rate0.18% | Tradable Shares52.18M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
BRIEF-Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma
Reuters · 04-02
Alpha Tau Medical Receives FDA Approval for Glioblastoma Trial
TIPRANKS · 04-02
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients With Recurrent Glioblastoma
THOMSON REUTERS · 04-02
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
GlobeNewswire · 04-02
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
ACCESS Newswire · 03-18
Alpha Tau Medical Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 03-17
Alpha Tau Medical Faces Uncertain Future Amid Clinical Trial Challenges
TIPRANKS · 03-14
Alpha Tau Medical Reports 2024 Earnings and Clinical Progress
TIPRANKS · 03-14
March 2025 Penny Stocks To Consider For Growth
Simply Wall St. · 03-03
Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences
TIPRANKS · 02-27
Alpha Tau to Participate in March Investor Conferences
GlobeNewswire · 02-27
Alpha Tau Medical Gets Medical Device Single Audit Program Certification
MT Newswires Live · 02-24
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
GlobeNewswire · 02-24
Alpha Tau Medical Gets FDA Approval to Expand DaRT Study in Pancreatic Cancer
MT Newswires Live · 02-03
Alpha Tau Announces FDA Approval of Ide Supplement to Expand Pilot Trial of Alpha Dart® to Thirty Patients With Pancreatic Cancer in Two Cohorts, With Locally Advanced or Metastatic Disease
THOMSON REUTERS · 02-03
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
GlobeNewswire · 02-03
Alpha Tau Medical Reports Promising Interim Data and Regulatory Milestones in Cancer Trials
TIPRANKS · 01-27
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to Be Shared at R&D Update Day
THOMSON REUTERS · 01-27
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
GlobeNewswire · 01-27
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
GlobeNewswire · 2024-12-18
Introduction
Company Name.
Alpha Tau Medical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App